Abstract
Introduction
This publication reviews the function of arginine vasopressin and focuses on the morphologic and functional correlation between the hormone and its effect on stress, the hypophysial–adrenocortical axis, neuroimmune responses, renal function and corticotroph pituitary tumors.
Materials and methods
A literature review was performed using various search engines for information regarding the morphology and the multifunctional role of arginine vasopressin.
Results
Although a large number of studies were published discussing these interactions, there are several important areas that are still obscure.
Conclusion
The questions of how does arginine vasopressin affect the morphology and function of these various areas, and how does the secretion of ACTH and adrenocortical hormones influence the morphology of arginine vasopressin-producing cells and their hormone secretion requires further investigation.
Similar content being viewed by others
References
Kamm O, Aldrich TB, Grote IW, Rowe LW, Bugbee EP (1928) The active principles of the posterior lobe of the pituitary gland: I. The demonstration of the presence of two active principles: II. The separation of the two principles and their concentration in the form of potent solid preparations. J Am Chem Soc 50(2):573–601
du Vigneaud V, Gish DT, Katsoyannis PG (1954) A synthetic preparation possessing biological properties associated with arginine-vasopressin. J Am Chem Soc 76:4751–4752
du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG (1954) The synthesis of oxytocin. J Am Chem Soc 76:3115–3121
Sachs H, Takabatake Y (1964) Evidence for a precursor in vasopressin biosynthesis. Endocrinology 75:943–948
Takabatake Y, Sachs H (1964) Vasopressin Biosynthesis. In vitro studies. Endocrinology 75:934–942
Sachs H, Fawcett P, Takabatake Y, Portanova R (1969) Biosynthesis and release of vasopressin and neurophysin. Recent Prog Horm Res 25:447–491
Oliver G, Schafer EA (1895) On the physiological action of extracts of pituitary body and certain other glandular organs: preliminary communication. J Physiol 18(3):277–279
Farini F (1913) Diabete insipido ed opoterapia. Gazz Osped Clin 34:1135–1139
Vongraven D (1913) Die nierenwirkung von hypophysenextrakten meschen. Berl Klin Wochenscgr 50:2083–2086
Oh YK (2008) Vasopressin and vasopressin receptor antagonists. Electrolyte Blood Press 6(1):51–55
Berczi I, Quintanar-Stephano A, Kovacs K (2009) Neuroimmune regulation in immunocompetence, acute illness, and healing. Ann NY Acad Sci 1153:220–239
Berczi I, Quintanar A, Campos R, Kovacs K (2012) Vasopressin, oxytocin and immune function. Adv Neuroimmune Biol 3(3–4):329–343
Richter D (1988) Molecular events in expression of vasopressin and oxytocin and their cognate receptors. Am J Physiol 255(2 Pt 2):F207–F219
Donaldson ZR, Young LJ (2008) Oxytocin, vasopressin, and the neurogenetics of sociality. Science 322(5903):900–904
Goodson JL (2008) Nonapeptides and the evolutionary patterning of sociality. Prog Brain Res 170:3–15
Burbach JP, Luckman SM, Murphy D, Gainer H (2001) Gene regulation in the magnocellular hypothalamo-neurohypophysial system. Physiol Rev 81(3):1197–1267
Rao VV, Loffler C, Battey J, Hansmann I (1992) The human gene for oxytocin–neurophysin I (OXT) is physically mapped to chromosome 20p13 by in situ hybridization. Cytogenet Cell Genet 61(4):271–273
Richter D (1983) Synthesis, processing, and gene structure of vasopressin and oxytocin. Prog Nucl Acid Res Mol Biol 30:245–266
Bolignano D, Cabassi A, Fiaccadori E, Ghigo E, Pasquali R, Peracino A et al (2014) Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med 52(10):1447–1456
Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A (2012) Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev 92(4):1813–1864
Schmidt A, Audigier S, Barberis C, Jard S, Manning M, Kolodziejczyk AS, Sawyer WH (1991) A radioiodinated linear vasopressin antagonist: a ligand with high affinity and specificity for V1a receptors. FEBS Lett 282(1):77–81
Li JD, Burton KJ, Zhang C, Hu SB, Zhou QY (2009) Vasopressin receptor V1a regulates circadian rhythms of locomotor activity and expression of clock-controlled genes in the suprachiasmatic nuclei. Am J Physiol Regul Integr Comp Physiol 296(3):R824–R830
Xu Y, Kim ER, Fan S, Xia Y, Xu Y, Huang C, Tong Q (2014) Profound and rapid reduction in body temperature induced by the melanocortin receptor agonists. Biochem Biophys Res Commun 451(2):184–189
Albers HE (2015) Species, sex and individual differences in the vasotocin/vasopressin system: relationship to neurochemical signaling in the social behavior neural network. Front Neuroendocrinol 36:49–71
Mittapalli G, Argaryan L, Brown SJ, Saldanha SA, Volmar CH, Ferguson J, Roberts E, Hodder P, Rosen H (2010–2013) Optimization and characterization of an antagonist for vasopressin 1a (V1a) receptor. Probe reports from the NIH Molecular Libraries Program [Internet]. National Center for Biotechnology Information (US), Bethesda
Barberis C, Audigier S (1985) Vasopressin and oxytocin receptors in the central nervous system of the rat. Ann Endocrinol (Paris) 46(1):35–39
Antoni FA (1984) Novel ligand specificity of pituitary vasopressin receptors in the rat. Neuroendocrinology 39(2):186–188
Born J, Pietrowsky R, Fehn HL (1998) Neuropsychological effects of vasopressin in healthy humans. Prog Brain Res 119:619–643
Thibonnier M, Coles P, Thibonnier A, Shoham M (2001) The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol 41:175–202
Thibonnier M, Preston JA, Dulin N, Wilkins PL, Berti-Mattera LN, Mattera R (1997) The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology 138(10):4109–4122
Kaufmann JE, Oksche A, Wollheim CB, Gunther G, Rosenthal W, Vischer UM (2000) Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest 106(1):107–116
Haberichter SL, Shi Q, Montgomery RR (2006) Regulated release of VWFand FVIII and the biologic implications. Pediatr Blood Cancer 46(5):547–553
North WG (2000) Gene regulation of vasopressin and vasopressin receptors in cancer. Exp Physiol 85:27S–40S
Iannucci NB, Ripoll GV, Garona J, Cascone O, Ciccia GN, Gomez DE, Alonso DF (2011) Antiproliferative effect of 10deamino-8-d-arginine vasopressin analogs on human breast cancer cells. Future Med Chem 3(16):1987–1993
Noh JM, Park W, Huh SJ, Cho EY, Choi Y, Lee JH, Bae DS (2009) Correlation between tumor volume response to radiotherapy and expression of biological markers in patients with cervical squamous cell carcinoma. J Gynecol Oncol 20(4):215–220
Wang FF, Tang KT, Yen YS, Ho DM, Yang AH, Hwang CI, Lin HD, Won JG (2012) Plasma corticotrophin response to desmopressin in patients with Cushing’s disease correlates with the expression of vasopressin receptor 2, but not with that of vasopressin 1 or 3, in their pituitary tumours. Clin Endocrinol (Oxf) 76(2):253–263
Kondo N, Arima H, Banno R, Kuwahara S, Sato I, Oiso Y (2004) Osmoregulation of vasopressin release and gene transcription under acute and chronic hypovolemia in rats. Am J Physiol 286(3):E337–E346
Dunn FL, Brennan TJ, Nelson AE, Robertson GI (1973) The role of blood osmolality and volume in regulating vasopressin secretion in the rat. J Clin Invest 52(12):3212–3219
Turner J, Sazonova O, Wang H, Pozzi A, Wagner GF (2010) Induction of the renal stanniocalcin-1 gene in rodents by water deprivation. Mol Cell Endocrinol 328(1–2):8–15
Bankir L, Bichet DG, Bouby N (2010) Vasopressin V2 receptors, ENaC, and sodium reabsorption: a risk factor for hypertension? Am J Physiol 299(5):917–928
Boone M, Deen PM (2008) Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption. Pflugers Arch 456(6):1005–1024
Sharabi FM, Schmid PG (1983) Evidence for a role of vasopressin in hypertension. Am J Nephrol 3(2–3):164–171
Bichet DG (1998) Nephrogenic diabetes insipidus. Am J Med 105(5):431–442
Bichet DG (2006) Nephrogenic diabetes insipidus. Adv Chronic Kidney Dis 13(2):96–104
Makaryus AN, McFarlane SI (2006) Diabetes Insipidus: diagnosis and treatment of a complex disease. Cleve Clin Med 73(1):65–71
Garofeanu CG, Weir M, Rosas-Arellano MP, Henson G, Garg AX, Clark WF (2005) Causes of reversible nephrogenic diabetes insipidus: a systematic review. Am J Kidney Dis 45(4):626–637
Sands JM, Bichet DG (2006) Nephogenic diabetes insipidus. Ann Int Med 144(3):186–194
Nagayama Y, Shigeno M, Nakagawa Y, Suganuma A, Takeshita A, Fujiyama K, Ashizawa K, Kiriyama T, Yokoyama N, Nagataki S (1994) Acquired nephrogenic diabetes insipidus secondary to distal renal tubular acidosis and nephrocalcinosis associated with Sjogren’s syndrome. J Endocrinol Invest 17(8):659–663
Bichet DG (2008) Vasopressin receptor mutations in nephrogenic diabetes insipidus. Semin Nephrol 28(3):245–251
Magaldi AJ (2000) New insights into the paradoxical effect of thiazides in diabetes insipidus therapy. Nephrol Dial Transplant 15(12):1903–1905
Moses AM, Notman DD (1982) Diabetes insipidus and syndrome of inappropriate antidiuretic hormone secretion (SIADH). Adv Intern Med 27:73–100
Nussbaum CE, Okawara SH, Jacobs LS (1991) Lymphocytic hypophysitis with involvement of the cavernous sinus and hypohalamus. Neurosurgery 28(3):440–444
Gregor NG, Kirkland RT, Clayton GW, Kirkland JL (1986) Central diabetes insipidus: 22 years’ experience. Am J Dis Child 140(6):551–554
Fujiwara TM, Morgan K, Bichet DG (1995) Molecular biology of diabetes insipidus. Annu Rev Med 46:331–343
Elias PC, Elias LL, Torres N, Moreira AC, Antunes-Rodrigues J, Castro M (2003) Progressive decline of vasopressin secretion in familial autosomal dominant neurohypophyseal diabetes insipidus presenting a novel mutation in vasopressin–neurophysin II gene. Clin Endocrinol (Oxf) 59(4):511–518
Perrotta S, Di Iorgi N, Ragione FD, Scianguetta S, Borriello A, Allegri A, Ferraro M, Santoro C, Napoli F, Calcagno A, Giaccardi M, Cappa M, Salerno MC, Cozzolino D, Maghnie M (2015) Early-onset of central diabetes insipidus is associated with de novo vasopressin–neurophysin II or Wolfram syndrome 1 gene mutations. Eur J Endocrinol 172(4):461–472
Tanoue A, Ito S, Honda K, Oshikawa S, Kitagawa Y, Koshimizu TA, Mori T, Tsujimoto G (2004) The vasopressin V1b receptor critically regulates hypothalamic–pituitary–adrenal axis activity under both stress and resting conditions. J Clin Invest 113(2):302–309
Ma S, Shipston MJ, Morilak D, Russell JA (2005) Reduced hypothalamic vasopressin secretion underlies attenuated adrenocorticotropin stress responses in pregnant rats. Endocrinology 146(3):1626–1637
Kovács KJ, Sawchenko PE (1996) Sequence of stress-induced alterations in indices of synaptic and transcriptional activation in parvocellular neurosecretory neurons. J Neurosci 16(1):262–273
Stewart LQ, Roper JA, Young WS 3rd, O’Carroll AM, Lolait SJ (2008) Pituitary–adrenal response to acute and repeated mild restraint, forced swim and change in environment stress in arginine vasopressin receptor 1b knockout mice. J Neuroendocrinol 20(5):597–605
de Goeij DC, Kvetnansky R, Whitnall MH, Jezova D, Berkenbosch F, Tilders FJ (1991) Repeated stress-induced activation of corticotropin-releasing factor neurons enhances vasopressin stores and colocalization with corticotropin-releasing factor in the median eminence of rats. Neuroendocrinology 53(2):150–159
Aguilera G, Subburaju S, Young S, Chen J (2008) The parvocellular vasopressinergic system and responsiveness of the hypothalamic pituitary adrenal axis during chronic stress. Prog Brain Res 170:29–39
Aguilera G (1998) Corticotropin releasing hormone, receptor regulation and the stress response. Trends Endocrinol Metab 9(8):329–336
Aguilera G (1994) Regulation of pituitary ACTH secretion during chronic stress. Front Neuroendocrinol 15:321–350
Sawchenko PE, Brown ER, Chan RK, Ericsson A, Li HY, Roland BL, Kovács KJ (1996) The paraventricular nucleus of the hypothalamus and the functional neuroanatomy of visceromotor responses to stress. Prog Brain Res 107:201–222
Turnbull AV, Rivier C (1997) Corticotropin-releasing factor (CRF) and endocrine responses to stress: CRF receptors, binding protein, and related peptides. Proc Soc Exp Biol Med 215(1):1–10
Vale W, Spiess J, Rivier C, Rivier J (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213(4514):1394–1397
Keller-Wood ME, Dallman MF (1984) Corticosteroid inhibition of ACTH secretion. Endocr Rev 5(1):1–24
Young WS 3rd, Mezey E, Siegel RE (1986) Quantitative in situ hybridization histochemistry reveals increased levels of corticotropin-releasing factor mRNA after adrenalectomy in rats. Neurosci Lett 70(2):198–203
Seasholtz A (2000) Regulation of adrenocorticotropic hormone secretion: lessons from mice deficient in corticotropin-releasing hormone. J Clin Invest 105(9):1187–1188
Owens MJ, Nemeroff CB (1991) Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 43(4):425–473
Tilders FJ, Schmidt ED, de Goeij DC (1993) Phenotypic plasticity of CRF neurons during stress. Ann NY Acad Sci 697:39–52
Watanabe T, Oth DN (1987) Detailed kinetic analysis of adrenocorticotropin secretion by dispersed rat anterior pituitary cells in a microperfusion system: effects of ovine corticotropin-releasing factor and arginine vasopressin. Endocrinol 121(3):1133–1145
Acharjee S, Do-rego JL, Oh DY, Ahn RS, Choe H, Vaudry H, Kim K, Seong JY, Kwon HB (2004) Identification of amino acid residues that direct differential ligand selectivity of mammalian and nonmammalian V1a type receptors for arginine vasopressin and vasotocin. Insights into molecular coevolution of V1a type receptors and their ligands. J Biol Chem 279(52):54445–54453
Vallotton MB (1991) The multiple faces of vasopressin receptors. Mol Cell Endocrinol 78(1–2):C73–C76
Patchev VK, Kalogeras KT, Zelazowski P, Wilder RL, Chrousos GP (1992) Increased plasma concentrations, hypothalamic content, and in vitro release of arginine vasopressin in inflammatory disease-prone, hypothalamic corticotropin-releasing hormone-deficient Lewis rats. Endocrinology 131(3):1453–1457
Patchev VK, Mastorakos G, Brady LS, Redwine J, Wilder RL, Chrousos GP (1993) Increased arginine vasopressin secretion may participate in the enhanced susceptibility of Lewis rats to inflammatory disease. Neuroendocrinology 58(1):106–110
Nagy E, Berczi I (1978) Immunodeficiency in hypophysectomized rats. Acta Endocrinol (Copenh) 89(3):530–537
Nagy E, Berczi I (1989) Pituitary dependence of bone marrow function. Br J Haematol 71(4):457–462
Turnbull AV, Rivier CL (1999) Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 79(1):1–71
Ray DW, Ren SG, Melmed S (1996) Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway. J Clin Invest 97(8):1852–1959
Naito Y, Fukata J, Masui Y, Hirai Y, Murakami N, Tominaga T, Nakai Y, Tamai S, Mori K, Imura H (1990) Interleukin-1 beta analogues with markedly reduced pyrogenic activity can stimulate secretion of adrenocorticotropic hormone in rats. Biochem Biophys Res Commun 167(1):103–109
Mastorakos G, Weber JS, Magiakou MA, Gunn H, Chrousos GP (1994) Hypothalamic–pituitary–adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab 79(4):934–939
Harbuz MS, Stephanou A, Sarlis N, Lightman SL (1992) The effects of recombinant human interleukin (IL)-1 alpha, IL-1 beta or IL-6 on hypothalamo-pituitary-adrenal axis activation. J Endocrinol 133(3):349–355
Ericsson A, Kovacs KJ, Sawchenko PE (1994) A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons. J Neurosci 14(2):897–913
Lee S, Rivier C (1994) Hypophysiotropic role and hypothalamic gene expression of corticotropin-releasing factor and vasopressin in rats injected with interleukin-1 beta systemically or into the brain ventricles. J Neuroendocrinol 6(2):217–224
Rivier C (1995) Blockade of nitric oxide formation augments adrenocorticotropin released by blood-borne interleukin-1 beta: role of vasopressin, prostaglandins, and alpha 1-adrenergic receptors. Endocrinology 136(8):3597–3603
Quintanar-Stephano A, Kovacs K, Berczi I (2004) Effects of neurointermediate pituitary lobectomy on humoral and cell-mediated immune responses in the rat. NeuroImmunoModulation 11(4):233–240
Quintanar-Stephano A, Organista-Esparza A, Chavira-Ramirez R, Kovacs K, Berczi I (2012) Effects of neurointermediate pituitary lobectomy and desmopressin on acute experimental autoimmune encephalomyelitis in Lewis rats. NeuroImmunoModulation 19(3):148–157
Campos-Rodriguez R, Quintanar-Stephano A, Jarillo-Luna RA, Oliver-Aguillon G, Ventura-Juarez J, Rivera-Aguilar V, Berczi I, Kovacs K (2006) Hypophysectomy and neurointermediate pituitary lobectomy reduce serum immunoglobulin M (IgM) and IgG and intestinal IgA responses to Salmonella enterica serovar Typhimurium infection in rats. Infect Immun 74(3):1883–1889
Quintanar-Stephano A, Abarca-Rojano E, Jarillo-Luna RA, Rivera-Aguilar V, Ventura-Juarez J, Berczi I, Kovacs K, Campos-Rodriguez R (2010) Hypophysectomy and neurointermediate pituitary lobectomy decrease humoral immune responses to T-independent and T-dependent antigens. J Physiol Biochem 66(1):7–13
Bell J, Adler MW, Greenstein JI (1992) The effect of arginine vasopressin on the autologous mixed lymphocyte reaction. Int J Immunopharmacol 14(1):93–103
Bell J, Adler MW, Greenstein JI, Liu-Chen LY (1993) Identification and characterization of [125I]arginine vasopressin binding sites on human peripheral blood mononuclear cells. Life Sci 52(1):95–105
Elands J, Resink A, De Kloet ER (1990) Neurohypophyseal hormone receptors in the rat thymus, spleen, and lymphocytes. Endocrinology 126(5):2703–2710
Hu SB, Zhao ZS, Yhap C, Grinberg A, Huang SP, Westphal H, Gold P (2003) Vasopressin receptor 1a-mediated negative regulation of B cell receptor signaling. J Neuroimmunol 135(1–2):72–81
Lolait SJ, O’Carroll AM, Mahan LC, Felder CC, Button DC, Young WS 3rd, Mezey E, Brownstein MJ (1995) Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci USA 92(15):6783–6787
Lloyd RV, Kovacs K, Young WF Jr, Farrell WE, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheithauer BW, Horvath E (2004) World Health Organization classification of tumours: pathology and genetics of tumours of endocrine organs. In: DeLellis R, RVL, Heitz PU, Eng C (eds) International Agency for Research on Cancer (IRAC), Lyon
Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S (1990) Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 71(6):1427–1433
Scott LV, Medbak S, Dinan TG (1999) ACTH and cortisol release following intravenous desmopressin: a dose-response study. Clin Endocrinol 51(5):653–658
Abe T, Tachikawa T, Sasaki A, Taniyama M, Okamura Y, Izumiyama H, Matsumoto K (2000) Histopathological and physiological characteristics of cultured human ACTH-secreting cells derived from a rapidly growing pituitary adenoma. Brain Tumor Pathol 17(3):133–138
Jard S (1988) Mechanisms of action of vasopressin and vasopressin antagonists. Kidney Int Suppl 26:S38–S42
Sakai Y, Horiba N, Tozawa F, Sakai K, Kuwayama A, Demura H, Suda T (1997) Desmopressin stimulation test for diagnosis of ACTH-dependent Cushing’s syndrome. Endocr J 44(5):687–695
Wang FF, Tang KT, Yen YS, Ho DM, Yang AH, Huang CI, Lin HD, Won JG (2012) Plasma corticotrophin response to desmopressin in patients with Cushing’s disease correlates with the expression of vasopressin receptor 2, but not with that of vasopressin receptor 1 or 3, in their pituitary tumours. Clin Endocrinol 76(2):253–263
Rene P, Grino M, Viollet C, Videau C, Jullian E, Bucchini D, Epelbaum J, Bertagna X, de Keyzer Y (2002) Overexpression of the V3 vasopressin receptor in transgenic mice corticotropes leads to increased basal corticosterone. J Neuroendocrinol 14(9):737–744
Rozengurt E, Legg A, Pettican P (1979) Vasopressin stimulation of mouse 3T3 cell growth. Proc Natl Acad Sci USA 76(3):1284–1287
Hunt NH, Perris AD, Sandford PA (1977) Role of vasopressin in the mitotic response of rat bone marrow cells to haemorrhage. J Endocrinol 72(1):5–16
Ghosh PM, Mikhailova M, Bedolla R, Kreisberg JI (2001) Arginine vasopressin stimulates mesangial cell proliferation by activating the epidermal growth factor receptor. Am J Physiol Renal Physiol 280(6):F972–F979
Russell WE, Bucher NL (1983) Vasopressin modulates liver regeneration in the Brattleboro rat. Am J Physiol 245(2):G321–G324
van Wijk PA, van Neck JW, Rijnberk A, Croughs RJ, Mol JA (1995) Proliferation of the murine corticotropic tumour cell line AtT20 is affected by hypophysiotrophic hormones, growth factors and glucocorticoids. Mol Cell Endocrinol 111(1):13–19
Subburaju S, Aguilera G (2007) Vasopressin mediates mitogenic responses to adrenalectomy in the rat anterior pituitary. Endocrinology 148(7):3102–3110
Nolan LA, Thomas CK, Levy A (2004) Pituitary mitosis and apoptotic responsiveness following adrenalectomy are independent of hypothalamic paraventricular nucleus CRH input. J Endocrinol 181(3):521–529
Horiba N, Suda T, Aiba M, Naruse M, Nomura K, Imamura M, Demura H (1995) Lysince vasopressin stimulation of cortisol secretion in patients with adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab 80(8):2336–2341
Abou-Samra AB, Harwood JP, Catt KJ, Aguilera G (1987) Mechanisms of action of CRF and other regulators of ACTH release in pituitary corticotrophs. Ann NY Acad Sci 512:67–84
Kuryshev YA, Childs GV, Ritchie AK (1996) Corticotropin-releasing hormone stimulates Ca2+ entry through L- and P-type Ca2+ channels in rat corticotropes. Endocrinology 137(6):2269–2277
Guerineau N, Corcuff JB, Tabarin A, Mollard P (1991) Spontaneous and corticotropin-releasing factor-induced cytosolic calcium transients in corticotrophs. Endocrinology 129(1):409–420
Lee AK, Tse A (1997) Mechanism underlying corticotropin-releasing hormone (CRH) triggered cytosolic Ca2+ rise in identified rat corticotrophs. J Physiol 504(Pt 2):367–378
Kuryshev YA, Haak L, Childs GV, Ritchie AK (1997) Corticotropin releasing hormone inhibits an inwardly rectifying potassium current in rat corticotropes. J Physiol 502(Pt 2):265–279
Abou-Samra AB, Catt KJ, Aguilera G (1986) Role of arachidonic acid in the regulation of adrenocorticotropin release from rat anterior pituitary cell cultures. Endocrinology 119(4):1427–1431
Won JG, Orth DN (1994) Role of lipoxygenase metabolites of arachidonic acid in the regulation of adrenocorticotropin secretion by perifused rat anterior pituitary cells. Endocrinology 135(4):1496–1503
Patel AJ, Honore E (2001) Properties and modulation of mammalian 2P domain K+ channels. Trends Neurosci 24(6):339–346
Lee AK, Smart JL, Rubinstein M, Low MJ, Tse A (2011) Reciprocal regulation of TREK-1 channels by arachidonic acid and CRH in mouse corticotropes. Endocrinology 152(5):1901–1910
Malerbi DA, Mendonca BB, Liberman B, Toledo SP, Corradini MC, Cunha-Neto MB, Fragoso MC, Wajchenberg BL (1993) The desmopressin stimulation test in the differential diagnosis of Cushing’s syndrome. Clin Endocrinol 38(5):463–472
Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M (2003) Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 88(12):5593–5602
Tabarin A, San Galli F, Dezou S, Leprat F, Corcuff JB, Latapie JL, Guerin J, Roger P (1990) The corticotropin-releasing factor test in the differential diagnosis of Cushing’s syndrome: a comparison with the lysine-vasopressin test. Acta Endocrinol (Copenh) 123(3):331–338
Newell-Price J, Perry L, Medbak S, Monson J, Savage M, Besser M, Grossman A (1997) A combined test using desmopressin and corticotropin-releasing hormone in the differential diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 82(1):176–181
Malerbi DA, Fragoso MC, Vieira Filho AH, Brenlha EM, Mendonca BB (1996) Cortisol and adrenocorticotropin response to desmopressin in women with Cushing’s disease compared with depressive illness. J Clin Endocrinol Metab 81(6):2233–2237
Alwani RA, Schmit Jongbloed LW, de Jong FH, van der Lely AJ, de Herder WW, Feelders RA (2014) Differentiating between Cushing’s disease and pseudo-Cushing’s syndrome: comparison of four tests. Eur J Endocrinol 170(4):477–486
Kaltsas GA, Giannulis MG, Newell-Price JD, Dacie JE, Thakkar C, Afshar F et al (1999) A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing’s disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 84(2):487–492
Kaskarelis IS, Tsatalou EG, Benakis SV, Malagari K, Komninos I, Vassiliadi D, Tsagarakis S, Thalassinos N (2006) Bilateral inferior petrosal sinuses sampling in the routine investigation of Cushing’s syndrome: a comparison with MRI. AJR Am J Roentgenol 187(2):562–570
Orth DN, DeBold CR, DeCherney GS, Jackson RV, Alexander AN, Rivier J, Spiess J, Vale W (1982) Pituitary macroadenomas causing Cushing’s disease respond to corticotropin-releasing factor. J Clin Endocrinol Metab 55(5):1017–1019
Acknowledgments
Authors are grateful to the Jarislowsky and Lloyd Carr-Harris foundations for their support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rotondo, F., Butz, H., Syro, L.V. et al. Arginine vasopressin (AVP): a review of its historical perspectives, current research and multifunctional role in the hypothalamo-hypophysial system. Pituitary 19, 345–355 (2016). https://doi.org/10.1007/s11102-015-0703-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-015-0703-0